Deep investigations into plasma p-tau 217 demonstrated its efficacy in differentiating amyloid-positive AD dementia patients from amyloid-negative non-AD BD patients, with a sensitivity of 93% and specificity of 89% (11). The gene discussed is MAPT; the disease is Alzheimer disease.